Infliximab News and Research

RSS
Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.
Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Anti-TNF therapy offers new hope to JDM patients

Anti-TNF therapy offers new hope to JDM patients

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

Real-world studies support switching IBD patients from reference infliximab to biosimilar infliximab

Real-world studies support switching IBD patients from reference infliximab to biosimilar infliximab

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab

Largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab

Brain imaging reveals distinctive aspects of high-inflammation depression

Brain imaging reveals distinctive aspects of high-inflammation depression

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Biosimilars show promise for children with IBD, but more research needed

Biosimilars show promise for children with IBD, but more research needed

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Researchers explore benefits and risks of biosimilar antibodies

Researchers explore benefits and risks of biosimilar antibodies